Introduction: Implementation of Nitrosamine Testing for Injectable Drug Products is a critical safety and regulatory requirement because parenteral drug products […]
Introduction: The immunogenicity of peptide-oligonucleotide conjugates is one of the most consequential development risks facing sponsors working with this rapidly
Introduction: PLGA Formulation Development Services encompass a highly specialized range of contract research capabilities aimed at transforming complex active pharmaceutical
Advanced Extractables & Leachables Testing for Ophthalmic Drug Products Evaluating extractables and leachables in ophthalmic formulations demands a detailed understanding
Introduction to Peptide-Oligonucleotide Conjugates Specification Setting Peptide-Oligonucleotide Conjugates Specification Setting is the systematic process of establishing scientifically justified physical, chemical,
Specification Setting and Acceptance Criteria for Peptide-Oligonucleotide Conjugates Read More »
Introduction: Selecting the correct sterilization methods for PLGA drug products is one of the most consequential decisions in pharmaceutical formulation
Introduction: Nitrosamine testing for metformin is no longer optional — it is a regulatory and patient safety requirement that every
Introduction: Lifecycle management strategies for dexamethasone injectables are essential for pharmaceutical manufacturers aiming to sustain product relevance, regulatory compliance, and
Lifecycle Management Strategies for Dexamethasone Injectables Read More »
Introduction: Method validation for extractables and leachables testing is a regulatory non-negotiable — without a fully documented, ICH Q2(R2)-compliant validation
Method Validation for Extractables and Leachables Testing: What ICH Q2(R2) Requires Read More »
Multi-Attribute Monitoring (MAM) for Therapeutic Peptide Characterization: A Modern LC-MS Workflow Introduction Liquid chromatography-mass spectrometry (LC-MS)-based Multi-Attribute Monitoring (MAM) has
